Chuo-ku, Japan

Toshiyuki Kusayama



Average Co-Inventor Count = 8.2

ph-index = 4

Forward Citations = 49(Granted Patents)


Location History:

  • Tsukuba, JP (2005 - 2009)
  • Chuo-ku, JP (2010 - 2011)
  • Tokyo, JP (2011)

Company Filing History:


Years Active: 2005-2011

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Toshiyuki Kusayama: A Pioneer in Invention

Introduction: Toshiyuki Kusayama, a visionary inventor hailing from Chuo-ku, JP, has carved a niche for himself in the realm of innovation. With an impressive portfolio of 5 patents to his name, Kusayama’s inventive prowess continues to shape the landscape of technological advancement.

Latest Patents: Among his latest patents is the ‘Benzimidazolylidene propane-1,3-dione derivative’, a compound designed as a potent GnRH receptor antagonist. This groundbreaking invention holds promise in the treatment of sex hormone-dependent diseases such as prostate cancer, breast cancer, and uterine leiomyoma, owing to its significant metabolic stability and minimal drug interactions.

Career Highlights: Throughout his career, Toshiyuki Kusayama has made significant contributions to the field of pharmaceuticals. He has lent his expertise to renowned companies such as Astellas Pharma GmbH and Yamanouchi Pharmaceutical Company Ltd., where his innovative spirit has thrived in the pursuit of cutting-edge medical solutions.

Collaborations: Kusayama’s collaborative efforts with esteemed coworkers Masaaki Hirano and Eiji Kawaminami have further propelled his inventions to new heights. Together, they have synergized their talents to push the boundaries of research and development, leading to novel discoveries in the realm of pharmaceuticals.

Conclusion: In conclusion, Toshiyuki Kusayama stands as a true pioneer in the world of invention, with a remarkable track record of turning visionary ideas into tangible realities. His relentless pursuit of innovation continues to inspire future generations of inventors and shape the landscape of technological advancement.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…